secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001193125-22-274514
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom secures $40M additional non-dilutive funding via revenue interest financing; total available up to $300M
--------------------------------------------------------------------------------

- Up to $40M committed: $15M on FDA approval of vonoprazan for EE and $25M on sales milestone.
- Total financing available under the agreement increases to up to $300M.
- Investors receive 10% royalty on net sales of vonoprazan products; reduced to 1% after certain annual thresholds following NERD approval.
- Total royalties capped at 2.0x payments received from investors; agreement terminates upon cap.
- New additional investor CO Finance LVS XXXVII LLC joined; existing investors include Sagard, NovaQuest, and Hercules (NYSE: HTGC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522274514/0001193125-22-274514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522274514/d392042d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-274514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer